New drug sits at the center of this dementia and brain health question.
For the estimated 5,000 to 7,000 Americans diagnosed with transthyretin amyloid cardiomyopathy each year, the treatment landscape has shifted dramatically. Three FDA-approved therapies now exist where none did before 2019, and a pipeline of gene-silencing and gene-editing treatments is advancing through clinical trials. The newest approval — vutrisiran, an RNA interference therapy marketed as AMVUTTRA — demonstrated a 36 percent reduction in all-cause mortality in its pivotal trial, offering a fundamentally different mechanism of attack against a disease that was, until recently, managed with little more than diuretics and supportive care. What makes this moment significant is not just the arrival of new drugs but the variety of approaches now available. Tafamidis stabilizes the transthyretin protein to prevent it from misfolding.
Acoramidis does the same thing but with near-complete stabilization. Vutrisiran silences the gene that produces the problematic protein altogether. Each works differently, each has different trade-offs in efficacy, cost, and administration, and each represents a genuine advance for patients and the cardiologists who treat them. Consider a 74-year-old man diagnosed with wild-type ATTR-CM two years ago — he now has options his doctors could not have offered even five years prior. This article examines the three approved therapies in detail, compares their clinical trial results, addresses the staggering cost barriers that still stand between patients and treatment, and looks ahead at emerging therapies including a one-time CRISPR gene-editing approach that could eventually make ongoing treatment unnecessary.
Table of Contents
- What New Drugs Are Changing the Outlook for Transthyretin Amyloid Cardiomyopathy Patients?
- How Effective Are the Latest ATTR-CM Treatments According to Clinical Trials?
- The Cost Crisis in ATTR-CM Treatment
- Gene Silencing Versus Protein Stabilization — Choosing Between Treatment Approaches
- Why ATTR-CM Remains Dangerously Underdiagnosed
- Emerging Therapies That Could Reshape ATTR-CM Treatment
- What the Future Holds for ATTR-CM Patients and Families
- Conclusion
- Frequently Asked Questions
What New Drugs Are Changing the Outlook for Transthyretin Amyloid Cardiomyopathy Patients?
The short answer: three drugs with three distinct mechanisms. Tafamidis, sold as Vyndaqel and Vyndamax by Pfizer, became the first FDA-approved treatment for ATTR-CM in May 2019. It works as a TTR stabilizer, binding to the transthyretin protein and preventing it from breaking apart into the amyloid fibrils that infiltrate heart tissue. Then in November 2024, BridgeBio’s acoramidis (brand name Attruby) earned approval as what the company describes as a “near-complete” TTR stabilizer — a more potent version of the same basic concept. Most recently, in March 2025, Alnylam’s vutrisiran (AMVUTTRA) became the first RNA interference therapy approved for ATTR-CM, working upstream by silencing the TTR gene itself so less of the protein gets produced in the first place. The distinction between stabilizers and silencers matters clinically.
Stabilizers like tafamidis and acoramidis leave the transthyretin protein circulating in the blood but prevent it from misfolding into toxic amyloid deposits. Gene-silencing therapies like vutrisiran reduce the total amount of transthyretin the liver produces. For patients with hereditary forms of the disease driven by genetic mutations, reducing the abnormal protein load may offer advantages. For wild-type ATTR-CM, which accounts for the majority of cases in older adults, both approaches have shown meaningful benefit in clinical trials — though the trials enrolled somewhat different patient populations, making direct head-to-head comparison difficult. A network meta-analysis published in the European Heart Journal attempted to compare relative risk reductions across all three approved therapies. It found that all three demonstrated superior net health benefits compared to no disease-specific therapy. The relative risk figures for mortality — vutrisiran at 0.04, acoramidis at 0.13, and tafamidis at 0.27 — suggest differences in efficacy, but the authors cautioned that differing trial designs limit the reliability of cross-trial comparisons.
How Effective Are the Latest ATTR-CM Treatments According to Clinical Trials?
The clinical evidence behind these drugs comes from large, well-designed trials. Acoramidis was evaluated in the ATTRibute-CM trial, which enrolled 632 patients and used a hierarchical win ratio as its primary endpoint. The drug achieved a win ratio of 1.8 over placebo, a statistically significant result with a p-value below 0.0001. At 30 months, all-cause mortality was 19.3 percent in the acoramidis group compared to 25.7 percent in the placebo group, and cardiovascular hospitalization rates were 26.7 percent versus 42.6 percent — a hazard ratio of 0.65 that translates to a number needed to treat of just seven. Open-label extension data at 42 months showed a 45 percent reduction in cardiovascular mortality risk for patients who received the drug continuously from the start, with a hazard ratio for all-cause mortality or first cardiovascular hospitalization of 0.57. Vutrisiran’s HELIOS-B trial enrolled 655 patients and followed them for up to 36 months in a double-blind design. The results were striking: a 36 percent reduction in all-cause mortality (hazard ratio 0.64), a 33 percent reduction in cardiovascular mortality (hazard ratio 0.67), and a 33 percent reduction in heart failure hospitalizations (rate ratio 0.67).
The drug also attenuated decline in left ventricular ejection fraction and slowed cardiac structural deterioration — outcomes that matter because ATTR-CM progressively thickens and stiffens the heart walls. However, there is a critical caveat. These trials compared each drug to placebo, not to each other. A patient or physician trying to decide between acoramidis and vutrisiran cannot simply line up the hazard ratios and pick the lower number. The patient populations differed, the trial durations differed, and the endpoints were not identical. The 2025 American College of Cardiology Concise Clinical Guidance for ATTR-CM evaluation and management reflects this expanded treatment landscape but does not rank one therapy over another. Treatment selection in practice depends on factors including disease subtype, patient preference for dosing schedule, insurance coverage, and whether the patient also has ATTR polyneuropathy — a condition for which vutrisiran, but not acoramidis, is also approved.
The Cost Crisis in ATTR-CM Treatment
The clinical promise of these therapies runs headlong into a pricing problem that puts them out of reach for many patients without robust insurance coverage. Tafamidis carries a list price between $268,000 and $282,300 per year. The Institute for Clinical and Economic Review analyzed the drug’s value and concluded it would be cost-effective only at $13,600 to $39,000 per year — meaning an 85 percent or greater discount from the list price would be needed to align cost with clinical benefit. Acoramidis is priced at approximately $18,759 per month, or roughly $244,000 per year. Vutrisiran’s pricing, while not detailed in the same way, is expected to fall in a comparable range given Alnylam’s pricing of its other RNAi therapies. These are not one-time costs. Both TTR stabilizers and vutrisiran require ongoing treatment. Tafamidis is taken daily by mouth.
Acoramidis is also an oral medication. Vutrisiran is a subcutaneous injection administered once every three months, which reduces the burden of frequent dosing but still requires indefinite continuation. For Medicare patients — and most ATTR-CM patients are over 65 — out-of-pocket costs can still be substantial even with Part D coverage, though manufacturer assistance programs exist. One notable commitment came from BridgeBio, which pledged to provide acoramidis free for life to patients who participated in the ATTRibute-CM trial. That gesture, while meaningful for the 632 trial participants, does not address the broader access problem. The tension between innovation and affordability in rare disease treatment is not new, but ATTR-CM is an instructive case because the disease is far more common than previously recognized. Up to 10 to 15 percent of older adults with heart failure may have unrecognized wild-type ATTR, and autopsy studies have found amyloid fibrils in cardiac tissue in roughly 25 percent of older adults. If diagnostic rates improve — as they should with better awareness and noninvasive diagnostic tools like technetium pyrophosphate scintigraphy — demand for these therapies will grow, and so will the fiscal pressure.
Gene Silencing Versus Protein Stabilization — Choosing Between Treatment Approaches
For the cardiologist deciding which therapy to recommend, the choice between stabilization and gene silencing involves practical trade-offs beyond the clinical trial numbers. TTR stabilizers preserve the protein in its functional tetrameric form. Transthyretin is not just a troublemaker — it serves as a carrier for thyroid hormone and retinol (vitamin A) in the bloodstream. Stabilizers keep that function intact. Gene-silencing therapies, by contrast, reduce total TTR production, which also reduces the protein’s physiological roles. Whether this matters clinically over the long term is not fully established, but it is a consideration that comes up in discussions of treatment selection. Dosing convenience is another differentiator.
Tafamidis and acoramidis are daily oral medications — familiar and straightforward, but dependent on patient adherence over years. Vutrisiran is injected subcutaneously once every three months, which some patients prefer because it removes the daily pill burden and can be administered in a clinical setting, ensuring compliance. For a patient with cognitive decline — relevant in this population, where dementia and ATTR-CM can coexist — a quarterly injection supervised by a healthcare team may be more reliable than daily self-administered pills. There is also the question of combination therapy. Could a patient benefit from both stabilizing whatever TTR remains in circulation and reducing the total amount produced? This is an active area of investigation, but no combination regimen has been tested in a large clinical trial. Physicians who attempt it are doing so off-label, without robust evidence to guide dosing or safety monitoring. The 2025 ACC guidance does not endorse combination therapy, and the cost of stacking two drugs already priced above $200,000 per year each makes this a difficult proposition for payers.
Why ATTR-CM Remains Dangerously Underdiagnosed
The treatment revolution means little for patients who never receive a diagnosis. ATTR-CM has historically been underrecognized for several reasons. Its symptoms — shortness of breath, fatigue, fluid retention, exercise intolerance — overlap almost entirely with more common forms of heart failure. Older patients are often assumed to have heart failure from hypertension or coronary artery disease. The condition does not show up on standard blood tests. And until recently, definitive diagnosis required an endomyocardial biopsy, an invasive procedure that most clinicians were reluctant to pursue in elderly patients. Noninvasive diagnosis has improved the situation considerably. Technetium pyrophosphate scintigraphy, a nuclear imaging scan, can identify ATTR cardiac amyloid with high sensitivity and specificity when combined with the exclusion of light-chain amyloidosis through blood and urine tests.
But the scan must be ordered, which means the clinician must first suspect the diagnosis. Red flags include heart failure with preserved or mildly reduced ejection fraction in a patient over 65, unexplained left ventricular wall thickening, a history of bilateral carpal tunnel syndrome (which often precedes cardiac symptoms by years), lumbar spinal stenosis, or a discrepancy between wall thickness on echocardiography and voltage on electrocardiogram. The prevalence data underscores the scope of the problem. At an estimated 41.1 cases per million people in the United States as of 2022, with roughly 12.7 new cases per million identified each year, ATTR-CM is still classified as a rare disease. But autopsy data suggesting amyloid fibrils in 25 percent of elderly hearts tells a different story. The true prevalence is almost certainly much higher than current diagnostic rates reflect. For families and caregivers reading this on a dementia care site, it is worth noting that ATTR amyloidosis can cause both cardiac and neurological symptoms. Hereditary forms caused by mutations in the TTR gene — particularly the Val122Ile variant, carried by an estimated 3 to 4 percent of African Americans — can present with polyneuropathy alongside cardiomyopathy.
Emerging Therapies That Could Reshape ATTR-CM Treatment
Beyond the three approved drugs, several pipeline therapies could further transform the field. Eplontersen, an antisense oligonucleotide developed by AstraZeneca and Ionis Pharmaceuticals, is being tested in the CARDIO-TTRansform Phase 3 trial — the largest ATTR-CM trial to date with 1,438 patients enrolled. It has FDA Fast Track designation, and results are expected to read out in 2026. Like vutrisiran, eplontersen reduces TTR protein production, but it uses a different molecular mechanism (antisense rather than RNA interference) and is administered as a monthly subcutaneous injection. Alnylam is also developing nucresiran, a next-generation siRNA that showed remarkable potency in Phase 1 testing — a single subcutaneous dose reduced serum TTR levels by more than 90 percent at 15 days and 96 percent by 29 days.
Phase 3 development plans are ongoing. Perhaps the most ambitious approach comes from Intellia Therapeutics, whose CRISPR-based therapy Nex-z aims to permanently inactivate the TTR gene with a single intravenous infusion. If successful, this would be a one-time treatment rather than a lifelong medication. However, the program encountered a serious setback when the FDA imposed a clinical hold on the MAGNITUDE trial for ATTR-CM on October 29, 2025, after a patient experienced Grade 4 liver toxicity with elevated transaminases and bilirubin. The FDA subsequently lifted the hold on the related MAGNITUDE-2 trial for hereditary ATTR polyneuropathy, but the episode highlights the risks inherent in gene-editing approaches and the long road still ahead before a curative therapy reaches the market.
What the Future Holds for ATTR-CM Patients and Families
The trajectory for ATTR-CM treatment is unmistakably positive, even accounting for the setbacks and cost barriers. Five years ago, patients had one approved therapy. Today they have three, with at least three more in advanced clinical development. The European Commission approved vutrisiran in June 2025, expanding access internationally, and additional long-term data presented at the ESC Congress in August 2025 continue to reinforce the durability of treatment benefits.
The 2025 ACC Concise Clinical Guidance now provides clinicians with an updated framework for evaluating and managing ATTR-CM in the context of this expanded therapeutic landscape. For families navigating dementia care who encounter ATTR-CM as a comorbidity or new diagnosis, the key takeaway is that this is no longer a disease without meaningful treatment. Early detection matters more than ever because the therapies work best when started before advanced cardiac damage has occurred. If a loved one has heart failure with thick heart walls, especially combined with a history of carpal tunnel surgery or spinal stenosis, asking the cardiologist about ATTR-CM screening is a reasonable and potentially life-altering step.
Conclusion
Transthyretin amyloid cardiomyopathy has moved from a diagnosis with limited options to one with three FDA-approved therapies and a robust pipeline of investigational treatments. Tafamidis stabilizes the TTR protein, acoramidis does so with greater potency, and vutrisiran silences the gene that produces it. Clinical trials have demonstrated reductions in mortality and cardiovascular hospitalization across all three drugs, and emerging approaches including antisense oligonucleotides, next-generation siRNAs, and CRISPR gene editing offer the possibility of even greater efficacy or one-time curative treatment in the years ahead.
The challenges that remain are significant — annual drug costs exceeding $200,000, widespread underdiagnosis particularly among older adults with heart failure, and unanswered questions about optimal treatment selection and combination therapy. But the direction of progress is clear. For patients and families affected by ATTR-CM, the most important step right now is ensuring an accurate and timely diagnosis so that the benefits of these new therapies can be realized before irreversible cardiac damage accumulates.
Frequently Asked Questions
What is transthyretin amyloid cardiomyopathy and how does it relate to dementia?
ATTR-CM is a condition where the transthyretin protein misfolds and deposits as amyloid fibrils in heart tissue, causing the heart to stiffen and fail. It relates to dementia care because hereditary forms of ATTR amyloidosis can also cause polyneuropathy with neurological symptoms, and because ATTR-CM predominantly affects older adults who may also be living with cognitive decline. The diseases share a patient population even when they are not directly linked.
How much do the new ATTR-CM drugs cost per year?
Tafamidis (Vyndaqel/Vyndamax) lists at approximately $268,000 to $282,300 per year. Acoramidis (Attruby) costs about $244,000 per year. The independent review body ICER has stated that tafamidis would only be cost-effective at $13,600 to $39,000 per year, representing an 85 percent or greater discount from list price. Patient assistance programs and insurance coverage can reduce out-of-pocket costs, but access remains a significant barrier.
How is ATTR-CM diagnosed without a biopsy?
A technetium pyrophosphate scintigraphy scan can noninvasively identify ATTR cardiac amyloid with high accuracy when combined with blood and urine tests to rule out light-chain (AL) amyloidosis. This has largely replaced endomyocardial biopsy as the diagnostic standard for suspected ATTR-CM, though biopsy may still be needed in ambiguous cases.
What is the difference between wild-type and hereditary ATTR-CM?
Wild-type ATTR-CM occurs when normal (non-mutated) transthyretin protein misfolds with aging and is the more common form, typically affecting men over 65. Hereditary ATTR-CM is caused by mutations in the TTR gene — the Val122Ile variant, found in an estimated 3 to 4 percent of African Americans, is the most common cardiac variant. Both forms cause similar cardiac symptoms, and both respond to the approved therapies, though hereditary forms may also involve nerve damage requiring additional treatment considerations.
Is there a cure for ATTR-CM?
No cure exists as of early 2026. Current FDA-approved therapies slow disease progression and reduce mortality but require ongoing treatment. The most promising curative approach is Intellia Therapeutics’ CRISPR-based gene-editing therapy Nex-z, which aims to permanently inactivate the TTR gene with a single infusion. However, it remains in Phase 3 trials and encountered a clinical hold in late 2025 due to a serious liver toxicity event. A true cure is likely still years away from clinical availability.
You Might Also Like
- Why Some Schizophrenia Patients Do Better With One Drug Over Another
- Why Some Patients on This Cancer Drug See Tumors Vanish Overnight
- The Drug That Gives Cancer Patients Their Appetite Back
For more, see National Institute on Aging.
